CompaniesNuvelution Pharma

Nuvelution Pharma

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

0

As Collaborator

3

Total Enrollment

505

By Phase

PHASE3: 2PHASE2/PHASE3: 1

By Status

COMPLETED: 2TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
Today
NCT03452943
NCT03567291
NCT03571256
Hover over trial bars to see details

Recent Trials

NCT03571256Collaborator
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
PHASE3Completed
158 participants
Started: May 31, 2018 · Completed: Dec 9, 2019
NCT03567291Collaborator
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
PHASE3Terminated
228 participants
Started: May 25, 2018 · Completed: May 15, 2020
NCT03452943Collaborator
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
PHASE2/PHASE3Completed
119 participants
Started: Feb 5, 2018 · Completed: Nov 12, 2019